Liu Xiuming, Teng Yuee, Wu Xin, Li Zhi, Bao Bowen, Liu Yunpeng, Qu Xiujuan, Zhang Lingyun
Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China.
Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
Front Oncol. 2020 May 5;10:695. doi: 10.3389/fonc.2020.00695. eCollection 2020.
Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) is an E3 ubiquitin-protein ligase and a signal-transducing adaptor protein involved in the development and progression of cancer. Despite the known functions of Cbl-b, its role in breast cancer remains unclear. The aim of this study is to explore the prognostic value of Cbl-b in breast cancer. Cbl-b expression was analyzed by immunohistochemistry in 292 breast cancer patients from the First Hospital of China Medical University between 1999 and 2008. Kaplan-Meier curve and Cox proportional hazards regression were used to analyze the independent prognostic factors for overall survival (OS) and disease-free survival (DFS). Nomogram was constructed based on these prognostic factors. Cbl-b expression was detected in 54.1% (158/292) breast cancer tissue samples. Cbl-b expression was correlated with DFS ( = 0.033), but was not significantly associated with the known clinic-pathological factors in this study. Log-rank analysis indicated that Cbl-b expression was correlated with better OS ( = 0.013) and DFS ( = 0.016). Multivariate analysis showed that Cbl-b expression was an independent prognostic factor in breast cancer. The nomogram we built for predicting OS was integrated with Cbl-b expression, age, tumor size, lymph node metastasis and histological grade. Except tumor size, all the above factors and date of diagnosis were used to construct the DFS nomogram. The C-indexes of the nomograms were 0.735 and 0.678, respectively. Our new clinical model was superior to the TNM staging for prediction of OS. Cbl-b expression independently predicts favorable prognosis in breast cancer. Cbl-b expression, combined with other variables could be more precise clinical predictive models for predicting OS and DFS in patients with breast cancer.
卡氏B淋巴细胞瘤原癌基因b（Cbl-b）是一种E3泛素蛋白连接酶，也是一种参与癌症发生和发展的信号转导衔接蛋白。尽管Cbl-b的功能已为人所知，但其在乳腺癌中的作用仍不清楚。本研究旨在探讨Cbl-b在乳腺癌中的预后价值。对1999年至2008年期间来自中国医科大学附属第一医院的292例乳腺癌患者的Cbl-b表达进行了免疫组织化学分析。采用Kaplan-Meier曲线和Cox比例风险回归分析总生存（OS）和无病生存（DFS）的独立预后因素。基于这些预后因素构建了列线图。在54.1%（158/292）的乳腺癌组织样本中检测到Cbl-b表达。Cbl-b表达与DFS相关（P = 0.033），但在本研究中与已知的临床病理因素无显著相关性。对数秩分析表明，Cbl-b表达与更好的OS（P = 0.013）和DFS（P = 0.016）相关。多因素分析显示，Cbl-b表达是乳腺癌的独立预后因素。我们构建的用于预测OS的列线图整合了Cbl-b表达、年龄、肿瘤大小、淋巴结转移和组织学分级。除肿瘤大小外，上述所有因素及诊断日期用于构建DFS列线图。列线图的C指数分别为0.735和0.678。我们的新临床模型在预测OS方面优于TNM分期。Cbl-b表达独立预测乳腺癌的良好预后。Cbl-b表达与其他变量相结合可为预测乳腺癌患者的OS和DFS提供更精确的临床预测模型。
